TTY Biopharm Company Limited (TPEX: 4105)

Market Cap	18.20B
Revenue (ttm)	5.73B
Net Income (ttm)	1.12B
Shares Out	248.65M
EPS (ttm)	4.51
PE Ratio	16.23
Forward PE	n/a
Dividend	3.50 (4.76%)
Ex-Dividend Date	Mar 28, 2024

Volume	139,154
Open	73.60
Previous Close	73.50
Day's Range	73.20 - 74.20
52-Week Range	69.50 - 87.00
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 342
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4105

Financial Performance

In 2023, TTY Biopharm Company's revenue was 5.51 billion, an increase of 8.77% compared to the previous year's 5.06 billion. Earnings were 1.13 billion, an increase of 3.12%.